Parallel Advisors’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Parallel Advisors’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-64,166	Closed	-$77	–	3510
2024 Q2	$77	Hold	64,166	–	–	﹤0.01%	3258
2024 Q1	$8.67K	Hold	64,166	–	–	﹤0.01%	2366
2023 Q4	$4.63K	Hold	64,166	–	–	﹤0.01%	2547
2023 Q3	$4.88K	Hold	64,166	–	–	﹤0.01%	2507
2023 Q2	$8.79K	Hold	64,166	–	–	﹤0.01%	2225
2023 Q1	$4.81K	Hold	64,166	–	–	﹤0.01%	2421
2022 Q4	$4.97K	Hold	64,166	–	–	﹤0.01%	2332
2022 Q3	$13K	Hold	64,166	–	–	﹤0.01%	1904
2022 Q2	$13K	Buy	64,166 +10,833	+20%	+$2.94K	﹤0.01%	1886
2022 Q1	$23K	Buy	53,333 +50,000	+1,500%	+$25.4K	﹤0.01%	1672
2021 Q4	$3K	Buy	+3,333	New	+$4.19K	﹤0.01%	2635

Parallel Advisors's EFTRW Position: Q3 2024 in Review

Parallel Advisors sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2024, closing a stake of 64,166 shares — an estimated $77 sold.

Parallel Advisors first reported a position in EFTRW in Q4 2021 and held it in 11 quarters. The position peaked at $23K in Q1 2022. 1 fund tracked by Wall St. Rank holds EFTRW as of Q3 2024.

Parallel Advisors reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
Parallel Advisors sold 64,166 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2024, an estimated $77.
Parallel Advisors first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q4 2021 and held it in 11 quarters.
Parallel Advisors's eFFECTOR Therapeutics, Inc. Warrant position peaked at $23K in Q1 2022.
1 fund tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.